OOIR: Observatory of International Research

Papers

(The H4-Index of Translational Neurodegeneration is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	339
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	307
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	191
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	176
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	149
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	130
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	111
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	98
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	95
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	93
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	92
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	89
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	83
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	81
Role of dopamine in the pathophysiology of Parkinson’s disease	79
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	71
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	69
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	69
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	67
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	65
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	65
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	65
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	63
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	63
Inflammasomes in neurodegenerative diseases	61

Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	61
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	58
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	57
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	56
Nose-to-brain drug delivery: from bench to bedside	53
Peripheral proteinopathy in neurodegenerative diseases	52
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	51
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	51
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	48
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	48
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	47
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	45
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	45
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	45
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	44
Multidimensional biomarkers for multiple system atrophy: an update and future directions	44
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	44
Perivascular spaces relate to the course and cognition of Huntington’s disease	43
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	43